Information Provided By:
Fly News Breaks for May 21, 2019
May 21, 2019 | 07:06 EDT
H.C. Wainwright analyst Edward White started Aeglea BioTherapeutics with a Buy rating and $20 price target. The company's capital raise in February removes the financial overhang from the stock, White tells investors in a research note. He believes Aeglea shares represent an attractive investment opportunity with several potential catalysts over the next 12 months.
News For AGLE From the Last 2 Days
There are no results for your query AGLE